Literature DB >> 7603339

Engineering human monoclonal antibody fragments: a recombinant enzyme-linked Fab.

R Burioni1, P Plaisant, M L Riccio, G M Rossolini, R Santangelo, A Vannini, G Satta.   

Abstract

A new plasmid vector, pCRP, allowing the expression of human recombinant monoclonal antibody Fab fragments fused with a bacterial acid phosphatase has been constructed. pCRP can accept heavy- and light-chain cDNAs cloned from combinatorial antibody libraries displayed on filamentous phages with the pCombIII system and is able to direct expression to soluble Fabs in which the carboxy-terminus of the heavy chain is fused to the amino-terminus of the mature PhoN nonspecific acid phosphatase of Providencia stuartii. Using the pCRP vector, we expressed two different human recombinant Fabs cloned from combinatorial libraries (one anti-tetenus toxoid and the other anti-HIV-1 gp120) fused with the acid phosphatase. In both cases chimeric antibodies were obtained which retained the antigen-binding ability and the enzymatic activity. Similar Fab-enzyme fusions can be successfully used, even unpurified, in enzyme immunoassays.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603339

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  2 in total

1.  Production and characterization of a human recombinant monoclonal Fab fragment specific for influenza A viruses.

Authors:  Alessandra Desogus; Roberto Burioni; Angela Ingianni; Francesca Bugli; Raffaello Pompei; Giovanni Fadda
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo.

Authors:  Nadeene E Riddick; Emilia A Hermann; Lamorris M Loftin; Sarah T Elliott; Winston C Wey; Barbara Cervasi; Jessica Taaffe; Jessica C Engram; Bing Li; James G Else; Yingying Li; Beatrice H Hahn; Cynthia A Derdeyn; Donald L Sodora; Cristian Apetrei; Mirko Paiardini; Guido Silvestri; Ronald G Collman
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.